-
08:03:07 PM

MRK - Merck & Co Inc

04/15/21 6:45 AM
NYSE : MRK
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviral therapeutic. Based on a planned interim analysis of
RHEA-AI
neutral
04/08/21 6:45 AM
NYSE : MRK
Merck's KEYTRUDA(R) (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, met its primary endpoint of disease-free survival (DFS) for the potential adjuvant treatment of patients with renal cell
RHEA-AI
neutral
03/30/21 6:45 AM
NYSE : MRK
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA(R) (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the European label for KEYTRUDA, Merck's anti-PD-1 therapy, be
RHEA-AI
very positive
03/29/21 4:15 PM
NYSE : MRK
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA(R) (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck's supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company's
RHEA-AI
very positive